



**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.05 Amendments to the Registrant's Code of Ethics, Waiver of Provision of the Code of Ethics.**

On March 10, 2016, as part of its periodic review of the corporate governance matters of CytoSorbents Corporation (the “Company”) and pursuant to the duties enumerated in their respective charters, the Audit Committee and the Nominating and Corporate Governance Committee of the Company’s Board of Directors amended and restated the Company’s Code of Business Conduct and Ethics (as amended, the “Code”) to provide certain information regarding the Company’s new Fraud and Ethics reporting hotline.

The foregoing summary of the Code is subject to, and qualified in its entirety by, reference to the full text of the Code, a copy of which is available at [www.cytosorbents.com](http://www.cytosorbents.com) under “Investor Relations- Governance Documents”.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 16, 2016 CYTOSORBENTS  
CORPORATION

By: /s/ Dr. Phillip P. Chan  
Name: Dr. Phillip P. Chan  
President and  
Title:  
Chief Executive Officer